XML 144 R87.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of preparation (Details)
€ in Millions, vaccine_dose in Millions
 1 Months Ended 12 Months Ended
Jul. 31, 2020
vaccine_dose
Dec. 31, 2024
EUR (€)
scenario
emission
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
Disclosure of initial application of standards or interpretations [line items]          
Average effective tax rate   18.00% 16.30% [1] 19.20% [1]  
Planet Care Program, net emissions by 2045 | emission   0      
Planet Care Program, percentage of reduction in scope 1 and 2 greenhouse gas by 2030   55.00%      
Planet Care Program, percentage of reduction in scope 3 greenhouse gas by 2030   30.00%      
Planet Care Program, percentage of reduction in all scopes greenhouse gas by 2030   90.00%      
Planet Care Program, percentage of renewably-sourced energy in all sites by 2030   100.00%      
Planet Care Program, number of global warming scenarios | scenario   3      
Other revenues   € 3,205 € 3,801 [2],[3] € 2,910 [2],[3]  
Current contract liabilities [4]   0 0 269  
Collaboration agreement with GSK          
Disclosure of initial application of standards or interpretations [line items]          
Current contract liabilities       269 € 319
Other revenue, doses no longer an obligation to be delivered     94    
Collaboration agreement with GSK | US Government          
Disclosure of initial application of standards or interpretations [line items]          
Number of vaccine doses to be supplied | vaccine_dose 100        
Other revenues     411    
Government grant recognised as deduction from development expenses   € 58 € 59 € 265  
Argentina          
Disclosure of initial application of standards or interpretations [line items]          
Cumulative inflation rate over three years     100.00%    
Turkey          
Disclosure of initial application of standards or interpretations [line items]          
Cumulative inflation rate over three years     100.00%    
[1] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[2] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[3] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[4] (a)See Note A.5., “Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK”. The year-on-year
change in this item between 2023 and 2022 includes revenue of €269 million recognized in profit or loss during 2023 (previously included in “Customer
contract liabilities” as of December 31, 2022).